Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Appoints Toni Hanninen as permanent chief financial officer, adding that he will now join the board as a director. Hanninen was appointed as interim CFO in September, having previously worked at Faron Pharmaceuticals Ltd. His permanent appointment becomes effective from January 1. Evgen also confirms that non-executive director, Susan Clement-Davies, will be retiring from the board.
Non-Executive Chair Susan Foden says: ‘I am very pleased to welcome Toni in as permanent CFO and I look forward to working with him on the board. Toni’s broad company experience is already making a difference to Evgen and he is providing considerable support to the rest of the executive team in driving projects forward.’
Current stock price: 1.50 pence
12-month change: down 67%
Copyright 2023 Alliance News Ltd. All Rights Reserved.